Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 10/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366608 | 0.95 | PDE9A (0.36) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6366229 | 0.83 | TSHR (0.46) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6366662 | 0.82 | PDE9A (0.42) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6368268 | 0.81 | PDE9A (0.42) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6368245 | 0.77 | ADORA2A (0.36) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6365678 | 0.75 | TSHR (0.39) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6366943 | 0.74 | ADORA2A (0.38) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6365341 | 0.73 | PDE9A (0.39) | PDE9APDE1CADORA2AADORA2BADORA1 | |
| SCHEMBL6371732 | 0.71 | MEN1 (0.39) | PDE9APDE1CPDE5APDE1APDE1B | |
| SCHEMBL6367456 | 0.71 | AR (0.43) | PDE9APDE1CCCNE1CDK2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE9A 6/4885PDE1C 101/4885ADORA2A 2845/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1C 41/4885ADORA2A 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.